Clinical trial of haplo-identical hematopoietic stem cell transplantation for treatment of refractory malignancies in children

Clinical trial of haplo-identical hematopoietic stem cell transplantation for treatment of refractory malignancies in children - Clinical trial of haplo-identical hematopoietic stem cell transplantation for treatment of refractory malignancies in children

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013692

Enrollment

Registered

2014-05-01

Start date

2014-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory malignancies

Interventions

Haplo-identical hematolopoietic stem cell transplantation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who relapsed after hamatopoietic stem cell transplantation using HLA-identical donor. 2.Patients with poor-prognosis or refractory malignancies who lack an HLA serological identical related donor and identical unrelated donor.

Exclusion criteria

Exclusion criteria: The patients whom the doctor judged to be unsuitable patient for this clinical trial.

Design outcomes

Primary

Measure	Time frame
3-year-survival in children who received haplo-identical hematopoietic stem cell transplantation.	—

Countries

Japan

Contacts

Public ContactHIdeaki Maeba

Kanazawa university pediareics

pedialib@med.kanazawa-u.ac.jp076-265-2313

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026